In:
RMD Open, BMJ, Vol. 6, No. 2 ( 2020-07), p. e001246-
Abstract:
This clinical case series describes our experience with the use of Janus kinase 1/2 inhibitor baricitinib in two patients suffering from refractory adult-onset Still’s disease (AOSD) as well as in one case suffering from AOSD-like autoinflammatory disease in the context of myelodysplastic syndrome. All patients suffered from disease non-responsive to conventional Disease-modifying antirheumatic drugs (DMARDs) as well as biological therapies including interleukin (IL)-1 and IL-6 blockade, relying instead on high daily doses of prednisolone. We also report the first case of Pneumocystis jirovecii infection following baricitinib use.
Type of Medium:
Online Resource
ISSN:
2056-5933
DOI:
10.1136/rmdopen-2020-001246
Language:
English
Publisher:
BMJ
Publication Date:
2020
detail.hit.zdb_id:
2812592-7